Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LIFE

LIFE - aTyr Pharma Inc Stock Price, Fair Value and News

$12.11-0.39 (-3.12%)
Market Closed

4/100

LIFE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

LIFE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LIFE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIFE Price Action

Last 7 days

-8.0%

Last 30 days

17.5%

Last 90 days

1452.6%

Trailing 12 Months

203.5%

LIFE RSI Chart

LIFE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIFE Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-16.03

Price/Sales (Trailing)

6.2K

EV/EBITDA

-16.05

Price/Free Cashflow

-19.13

LIFE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LIFE Fundamentals

LIFE Revenue

Revenue (TTM)

190.0K

Rev. Growth (Qtr)

-100%

LIFE Earnings

Earnings (TTM)

-74.1M

Earnings Growth (Yr)

6.7%

Earnings Growth (Qtr)

45.66%

LIFE Profitability

EBT Margin

-39012.11%

Return on Equity

-110.09%

Return on Assets

-79.65%

Free Cashflow Yield

-5.23%

LIFE Investor Care

Shares Dilution (1Y)

10.35%

Diluted EPS (TTM)

-0.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202500190.0K190.0K
2024323.5K294.0K264.5K235.0K
20237.9M5.4M2.9M353.0K
202200010.4M
20202.9M5.4M7.9M10.5M
2019000422.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About aTyr Pharma Inc

LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
 CEO
 WEBSITEatyrpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES65

aTyr Pharma Inc Frequently Asked Questions

LIFE is the stock ticker symbol of aTyr Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of aTyr Pharma Inc is 1.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, LIFE's PE ratio (Price to Earnings) is -16.03 and Price to Sales (PS) ratio is 6.25 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIFE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, aTyr Pharma Inc has provided 0.082 (multiply by 100 for percentage) rate of return.